MX350024B - Formas polimorfas del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2- benzisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro-2h-p iran-4-carboxílico. - Google Patents

Formas polimorfas del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2- benzisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro-2h-p iran-4-carboxílico.

Info

Publication number
MX350024B
MX350024B MX2013013355A MX2013013355A MX350024B MX 350024 B MX350024 B MX 350024B MX 2013013355 A MX2013013355 A MX 2013013355A MX 2013013355 A MX2013013355 A MX 2013013355A MX 350024 B MX350024 B MX 350024B
Authority
MX
Mexico
Prior art keywords
methyl
trifluoroethoxy
pyran
piperidin
tetrahydro
Prior art date
Application number
MX2013013355A
Other languages
English (en)
Other versions
MX2013013355A (es
Inventor
Noguchi Hirohide
Kojima Takashi
Numata Toyoharu
Waizui Nobuaki
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Publication of MX2013013355A publication Critical patent/MX2013013355A/es
Publication of MX350024B publication Critical patent/MX350024B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a novedosas formas cristalinas del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il] oxi}metil)piperidin-1-il]metil}-tetrahidro-2H-piran-4-carboxílico . Más particularmente, la invención se relaciona con formas polimórficas (Forma Polimorfa I o Forma Polimorfa II), y procesos para la preparación de, y a composiciones que las contienen, así como también a usos de tales formas polimórficas.
MX2013013355A 2011-05-18 2012-05-18 Formas polimorfas del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2- benzisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro-2h-p iran-4-carboxílico. MX350024B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011111901 2011-05-18
PCT/JP2012/003288 WO2012157288A1 (en) 2011-05-18 2012-05-18 Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid

Publications (2)

Publication Number Publication Date
MX2013013355A MX2013013355A (es) 2014-01-08
MX350024B true MX350024B (es) 2017-08-23

Family

ID=47176633

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013355A MX350024B (es) 2011-05-18 2012-05-18 Formas polimorfas del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2- benzisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro-2h-p iran-4-carboxílico.

Country Status (13)

Country Link
US (1) US9187463B2 (es)
EP (1) EP2710002B1 (es)
JP (1) JP5608873B2 (es)
KR (3) KR102459766B1 (es)
CN (1) CN103702995B (es)
BR (1) BR112013029319A2 (es)
CA (1) CA2836372C (es)
ES (1) ES2618494T3 (es)
HK (2) HK1195066A1 (es)
MX (1) MX350024B (es)
RU (1) RU2616978C2 (es)
TW (1) TWI537265B (es)
WO (1) WO2012157288A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2922849B1 (en) * 2012-11-21 2017-07-12 RaQualia Pharma Inc. Polymorphs of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid as 5-hydroxytryptamine-4 (5-ht4) receptor agonists for the treatment of gastrointestinal diseases
NZ733234A (en) 2014-03-06 2018-08-31 Aratana Therapeutics Inc Crystalline forms of grapiprant
KR102270323B1 (ko) 2014-03-06 2021-06-29 아라타나 세라퓨틱스, 인크. 그라피프란트의 조성물 및 이를 사용하기 위한 방법
TWI672300B (zh) * 2014-05-20 2019-09-21 日商拉夸里亞創藥股份有限公司 苯并異唑衍生物鹽類
KR20230022038A (ko) 2021-08-06 2023-02-14 주식회사 엘지에너지솔루션 건식 전극 필름 제조 방법 및 상기 전극 필름 제조 시스템

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
ES2144355B1 (es) * 1997-12-30 2001-01-01 Ferrer Int Compuestos derivados del cromeno.
US8816090B2 (en) 2005-02-25 2014-08-26 Pfizer Inc. Benzisoxazole derivatives
SG183111A1 (en) 2010-02-16 2012-09-27 Pfizer (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors
DK2688648T3 (en) * 2011-03-23 2016-03-14 Raqualia Pharma Inc 5-HT 4 receptor agonist as a prokinetic agent

Also Published As

Publication number Publication date
CA2836372A1 (en) 2012-11-22
US20140187583A1 (en) 2014-07-03
JP5608873B2 (ja) 2014-10-15
EP2710002A4 (en) 2014-10-01
EP2710002B1 (en) 2017-03-01
ES2618494T3 (es) 2017-06-21
JP2014513665A (ja) 2014-06-05
HK1195066A1 (zh) 2014-10-31
CN103702995B (zh) 2016-04-13
BR112013029319A2 (pt) 2017-01-31
KR20190015614A (ko) 2019-02-13
CA2836372C (en) 2020-09-22
HK1195559A1 (zh) 2014-11-14
KR20140041524A (ko) 2014-04-04
KR102459766B1 (ko) 2022-10-26
US9187463B2 (en) 2015-11-17
CN103702995A (zh) 2014-04-02
RU2013156069A (ru) 2015-06-27
KR20210104170A (ko) 2021-08-24
RU2616978C2 (ru) 2017-04-19
TWI537265B (zh) 2016-06-11
EP2710002A1 (en) 2014-03-26
MX2013013355A (es) 2014-01-08
WO2012157288A1 (en) 2012-11-22
TW201300382A (zh) 2013-01-01

Similar Documents

Publication Publication Date Title
WO2011110876A8 (en) Novel salts for the manufacture of pharmaceutical compositions
MX361020B (es) Procesos para preparar compuestos heterociclicos, incluida trans-7-oxo-6-(sulfooxi)-1,6-diazabiciclo [3,2,1]octano-2-carboxam ida y sales de la misma.
TW201129555A (en) Process for the manufacture of dabigatrane etexilate
MD20140002A2 (ro) Indazoli
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
SG195319A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
IN2014MN02459A (es)
MX2010012390A (es) Derivados de indazoles sustituidos con fenilo o piridinilo.
GEP20217235B (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
MX347841B (es) Procedimiento para preparar derivados de antranilamida sustituidos con tetrazoles y polimorfos cristalinos novedosos de estos derivados.
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
ME00680B (me) Nova jedinjenja diozmetina, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže
WO2014188453A3 (en) Novel process for the preparation of 2-[4-(2-{4-[1-(2-ethoxyethyl)-1h-benzimidazol-2-yl]-1-piperidinyl}ethyl) phenyl]-2-methylpropanoic acid
MX350024B (es) Formas polimorfas del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2- benzisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro-2h-p iran-4-carboxílico.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MX350862B (es) Acidos de piperidinil naftilacetico.
PL401473A1 (pl) Nowe, silnie fluorescencyjne substancje heterocykliczne i sposób ich otrzymywania
IN2014DN06122A (es)
UA109460C2 (uk) N-гетарилметилпіразолілкарбоксаміди
MX353994B (es) Formas polimorfas.
MX339513B (es) Derivados de sec-hidroxiciclohexilo como inhibidores de lipasa sensible a hormonas (hsl) para el tratamiento de diabetes.
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
WO2014195593A3 (fr) Composes inhibiteurs de l'acetylcholinesterase et agonistes des recepteurs serotoninergiques 5ht4, a effet promnesiant, leurs procedes de preparation et compositions pharmaceutiques les contenant
UA110822C2 (uk) Піперидинілмонокарбонові кислоти як агоністи s1p1-рецепторів
MX2016014948A (es) Sales derivadas de bencisoxazol.

Legal Events

Date Code Title Description
FG Grant or registration